Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

Investigators reported on detection rates for cancers and precancers in a group of 350 individuals presenting for standard of care colonoscopy.

The company saw orders for its Cologuard colorectal cancer test fall 63 percent during the first 20 days of April because of a decline in standard healthcare visits.

The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.

The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.

For full-year 2019, the company reported total revenues of €1.1 million, down 27 percent year over year mainly due to a decrease in licensing revenue from China.

In Q1, the US represented more than 40 percent of new Idylla instrument placements, but growth stalled due to COVID-19.

The company said that despite the uptick, the COVID-19 pandemic has negatively affected orders for its Cologuard colorectal cancer screening test.

The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.

The researchers identified specific macrophage and conventional dendritic cell subsets as key mediators of cellular crosstalk in the tumor microenvironment.

A new paper outlines an upcoming effort to trace tumor development and trajectory in time and space using single-cell genetics and other genomic methods.

Pages

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.